1. Confidential Presenting Gonexin December 13, 2001 Providing hope through extension and enhancement of life MBA Consulting Team Larry Morkre Matt Narens Rick Silva, Ph.D. Brian Weninger

2. Confidential Concept Gonexin is a revolutionary, patented “smart drug” for cancer treatment. We have the expertise to guide Gonexin to commercial success in a market with huge profit potential.

3. Confidential Management and Leadership Dr. Paul Jarosz Chief Operating Officer Involved in commercial development of 58 pharmaceutical products Clinical development executive with Geneva Pharmaceuticals (Novartis), Johnson & Johnson, and Syntex (Roche) Introduction Opportunity Technology Financial Summary Questions

4. Confidential Dr. Terry Nett Cofounder and board member Internationally recognized expert in GnRH biology Dr. Mike Glode Cofounder and board member Internationally recognized researcher in prostate cancer biology Consultant on clinical trials for Leupron and Abarelix Management and Leadership Introduction Opportunity Technology Financial Summary Questions

5. Confidential Global Pharmaceutical Market $400 B 2003 Introduction Opportunity Technology Financial Summary Questions

6. Confidential Industry Trends Trend away from toxic to “smart drugs” Shift from healthcare spending to pharmaceutical spending Small R & D firms have innovative advantage Introduction Opportunity Technology Financial Summary Questions

7. Confidential Market Growth Potential Up to 15% growth in human pharmaceutical market High risk begins at age 50 Aging population Introduction Opportunity Technology Financial Summary Questions

8. Confidential Our Position Introduction Opportunity Technology Financial Summary Questions

9. Confidential Market Share Growth 79,000 late stage cases of prostate cancer treated annually Introduction Opportunity Technology Financial Summary Questions

10. Confidential Industry publications Marketing Strategy Introduction Opportunity Technology Financial Summary Questions

11. Confidential Marketing Strategy Trade shows Introduction Opportunity Technology Financial Summary Questions

12. Confidential Annual scientific and clinical meetings Marketing Strategy Dedicated direct sales team Web presence Introduction Opportunity Technology Financial Summary Questions

13. Confidential Bright Future We are an innovative Research and Development organization Other potential indications for Gonexin –Breast cancer –Colon cancer –Uterine cancers –Pancreatic cancer –Some forms of lung cancer Introduction Opportunity Technology Financial Summary Questions

14. Confidential The Product Two therapeutic indications- Prostate Cancer Hormone therapy Chemotherapy Gonexin Other Epithelial Cancers Introduction Opportunity Technology Financial Summary Questions Leupron, Zolodex, and Viadur only offer hormone therapy mechanism

15. Confidential Normal Physiology Gonadotroph GnRH Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

16. Confidential Gonadotroph GnRH Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions Normal Physiology

17. Confidential Gonadotroph GnRH Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions Normal Physiology

18. Confidential Gonadotroph GnRH Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions Normal Physiology

19. Confidential Gonadotroph GnRH Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions Normal Physiology

20. Confidential Gonadotroph GnRH Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions Normal Physiology

21. Confidential Gonadotroph GnRH Non Target Cell Receptor Testosterone Introduction Opportunity Technology Financial Summary Questions Normal Physiology

22. Confidential Gonadotroph GnRH Non Target Cell Receptor Testosterone Introduction Opportunity Technology Financial Summary Questions Normal Physiology

23. Confidential Gonadotroph GnRH Non Target Cell Receptor Testosterone Introduction Opportunity Technology Financial Summary Questions Normal Physiology

24. Confidential Gonadotroph GnRH Non Target Cell Receptor Testosterone Introduction Opportunity Technology Financial Summary Questions Normal Physiology

25. Confidential Gonadotroph GnRH Non Target Cell Receptor Testosterone Introduction Opportunity Technology Financial Summary Questions Normal Physiology

26. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

27. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

28. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

29. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

30. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

31. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

32. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

33. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

34. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

35. Confidential Hormone Therapy Mechanism Gonadotroph Leupron Non Target Cell Receptor Introduction Opportunity Technology Financial Summary Questions

36. Confidential Hormone Therapy Mechanism GonadotrophNon Target Cell Receptor Testosterone Introduction Opportunity Technology Financial Summary Questions GnRH

37. Confidential Chemotherapy Mechanism Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Introduction Opportunity Technology Financial Summary Questions

38. Confidential Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

39. Confidential Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

40. Confidential Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

41. Confidential Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

42. Confidential Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

43. Confidential Gonadotroph GnRH-Toxin Non Target Cell Receptor CancerHealthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

44. Confidential Gonadotroph Cancer GnRH-Toxin Non Target Cell Receptor Healthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

45. Confidential GnRH-Toxin Non Target Cell Receptor Healthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

46. Confidential GnRH-Toxin Non Target Cell Receptor Healthy Cell Receptor GnRH-Toxin Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

47. Confidential Non Target Cell Healthy Cell Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

48. Confidential Non Target Cell Healthy Cell Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

49. Confidential Non Target Cell Healthy Cell Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

50. Confidential Non Target Cell Healthy Cell Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions

51. Confidential Key to Success FDA Approval –Safety of treatment –Efficacy of treatment Introduction Opportunity Technology Financial Summary Questions

52. Confidential Introduction Opportunity Technology Financial Summary Questions a a $136 million premoney valuation Funding & Development Schedule

53. Confidential Profit Growth Profit Introduction Opportunity Technology Financial Summary Questions

54. Confidential Summary Promising, patented “smart drug” Market of over $2.6 billion annually Precedence for capture of 80% of market Demographic shift will catalyze market growth Foundation for a management team with a track record of drug commercialization Introduction Opportunity Technology Financial Summary Questions

55. Confidential Questions Introduction Opportunity Technology Financial Summary Questions

56. Confidential Questions Introduction Opportunity Technology Expertise Financial Summary Questions

57. Confidential Funding Required YearFunding Required Milestone% EquityIRR 1$3 MScientific Proof of Concept 17%45% 2$5 MDrug Safety, Phase I 16.7%40% 3$15 MPhase II29.8%33% 5$43.5 M IPO a Phase III 33% (96.5%) 29% Introduction Opportunity Technology Expertise Financial Summary Questions a $136 million premoney valuation

58. Confidential Gonexin Price Hormonal Treatment AdministerInsurance Cost Urologist Cost Difference Gonexin ™ Once$9,500$5,500$4,000 Introduction Opportunity Technology Expertise Financial Summary Questions

59. Confidential Pricing Strategy Hormonal Treatment AdministerInsurance Cost Urologist Cost Difference ViadurOnce/ Year$5,650 SurgeryOnce$4,000N/A Lupron Depot Once/ Quarter $1,500$750 ZolodexOnce/ Quarter $1,125$675$450 Introduction Opportunity Technology Expertise Financial Summary Questions

60. Confidential Development Timeline Introduction Opportunity Technology Expertise Financial Summary Questions

61. Confidential Development Timeline Introduction Opportunity Technology Expertise Financial Summary Questions

62. Confidential Introduction Opportunity Technology Expertise Financial Summary Questions Testosterone levels Leupron Abarelix (Planexis) Exogenous Testosterone Removal of GnRH agonist Or antagonist

63. Confidential Market Over 198,000 men diagnosed with prostate cancer each year 2 nd leading cause of male cancer death in the US Introduction Opportunity Technology Expertise Financial Summary Questions

64. Confidential Earnings and Cash Flow Introduction Opportunity Technology Expertise Financial Summary Questions